Personalis Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
225
- Stock Symbol
-
PSNL
- Share Price
-
$3.56
- (As of Friday Closing)
Personalis General Information
Description
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Contact Information
Website
www.personalis.comCorporate Office
- 6600 Dumbarton Circle
- Fremont, CA 94555
- United States
Corporate Office
- 6600 Dumbarton Circle
- Fremont, CA 94555
- United States
Personalis Stock Performance
As of 21-Mar-2025, Personalis’s stock price is $3.56. Its current market cap is $314M with 88.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.56 | $3.61 | $1.14 - $7.20 | $314M | 88.3M | 1.24M | -$1.37 |
Personalis Financials Summary
As of 31-Dec-2024, Personalis has a trailing 12-month revenue of $84.6M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 391,031 | 391,031 | 29,584 | (52,902) |
| Revenue | 84,614 | 84,614 | 73,481 | 65,047 |
| EBITDA | (75,811) | (75,811) | (102,708) | (107,038) |
| Net Income | (81,284) | (81,284) | (108,296) | (113,315) |
| Total Assets | 270,268 | 270,268 | 225,099 | 292,700 |
| Total Debt | 44,247 | 44,247 | 47,728 | 48,650 |
Personalis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Personalis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Personalis Comparisons
Industry
Financing
Details
Personalis Competitors (39)
One of Personalis’s 39 competitors is Tempus AI, a Formerly VC-backed company based in Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tempus AI | Formerly VC-backed | Chicago, IL | ||||
| Parexel International | Private Equity-Backed | Durham, NC | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Champions Oncology | Formerly VC-backed | Hackensack, NJ | ||||
| Caris Life Sciences | Private Equity-Backed | Irving, TX |
Personalis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Personalis Patents
Personalis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4427227-A1 | Determining fragmentomic signatures based on latent variables of nucleic acid molecules | Pending | 01-Nov-2021 | ||
| US-20230103464-A1 | Customized assays for personalized cancer monitoring | Pending | 05-Oct-2021 | ||
| EP-4413580-A1 | Customized assays for personalized cancer monitoring | Pending | 05-Oct-2021 | ||
| EP-4327327-A1 | Detecting loss of heterozygosity in hla alleles using machine-learning models | Pending | 22-Apr-2021 | ||
| US-20240185952-A1 | Detecting loss of heterozygosity in hla alleles using machine-learning models | Pending | 22-Apr-2021 | G16B20/20 |
Personalis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Personalis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Personalis ESG
Risk Overview
Risk Rating
Updated June, 30, 2022
20.41 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile
Pharmaceuticals
Industry
of 905
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 66
Rank
Percentile
Personalis FAQs
-
When was Personalis founded?
Personalis was founded in 2011.
-
Where is Personalis headquartered?
Personalis is headquartered in Fremont, CA.
-
What is the size of Personalis?
Personalis has 225 total employees.
-
What industry is Personalis in?
Personalis’s primary industry is Drug Discovery.
-
Is Personalis a private or public company?
Personalis is a Public company.
-
What is Personalis’s stock symbol?
The ticker symbol for Personalis is PSNL.
-
What is the current stock price of Personalis?
As of 21-Mar-2025 the stock price of Personalis is $3.56.
-
What is the current market cap of Personalis?
The current market capitalization of Personalis is $314M.
-
What is Personalis’s current revenue?
The trailing twelve month revenue for Personalis is $84.6M.
-
Who are Personalis’s competitors?
Tempus AI, Parexel International, Inovio Pharmaceuticals, Champions Oncology, and Caris Life Sciences are some of the 39 competitors of Personalis.
-
What is Personalis’s annual earnings per share (EPS)?
Personalis’s EPS for 12 months was -$1.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
